These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 9825730)
21. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?]. Carnaghi C; Zucali P; Garassino I Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298 [TBL] [Abstract][Full Text] [Related]
22. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase. Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097 [TBL] [Abstract][Full Text] [Related]
24. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma. Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664 [TBL] [Abstract][Full Text] [Related]
25. Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. Shimoyama S; Mochizuki Y; Kusada O; Kaminishi M Int J Oncol; 2002 Sep; 21(3):643-8. PubMed ID: 12168112 [TBL] [Abstract][Full Text] [Related]
26. Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer. Richter SN; Nadai M; Palumbo M; Palù G Cancer Chemother Pharmacol; 2009 Jun; 64(1):199-200. PubMed ID: 19288104 [TBL] [Abstract][Full Text] [Related]
27. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan]. Xu JM; Li YM; Wang Y; Zhao CH; Yuan SJ; Yang WW; Li ZQ; Han Y; Azzariti A; Paradiso A Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):578-82. PubMed ID: 17236550 [TBL] [Abstract][Full Text] [Related]
28. Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy. Hofmann C; Buttenschoen K; Straeter J; Henne-Bruns D; Kornmann M Anticancer Res; 2005; 25(2A):795-804. PubMed ID: 15868911 [TBL] [Abstract][Full Text] [Related]
29. Chemotherapy for colorectal cancer. Goyle S; Maraveyas A Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107 [TBL] [Abstract][Full Text] [Related]
30. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Davidson D; Coulombe Y; Martinez-Marignac VL; Amrein L; Grenier J; Hodkinson K; Masson JY; Aloyz R; Panasci L Invest New Drugs; 2012 Jun; 30(3):1248-56. PubMed ID: 21221710 [TBL] [Abstract][Full Text] [Related]
31. In vitro cytotoxicity, pharmacokinetics and tissue distribution in rats of MXN-004, a novel conjugate of polyethylene glycol and SN38. Zhou S; Li N; Wang X; Li C; Tian F; Ren S; Zhang Y; He Y; Qiu Z; Zhao D; Chen X Xenobiotica; 2014 Jun; 44(6):562-9. PubMed ID: 24308437 [TBL] [Abstract][Full Text] [Related]
33. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Aschele C; Baldo C; Sobrero AF; Debernardis D; Bornmann WG; Bertino JR Clin Cancer Res; 1998 May; 4(5):1323-30. PubMed ID: 9607593 [TBL] [Abstract][Full Text] [Related]
34. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins. Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089 [TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. Chester JD; Joel SP; Cheeseman SL; Hall GD; Braun MS; Perry J; Davis T; Button CJ; Seymour MT J Clin Oncol; 2003 Mar; 21(6):1125-32. PubMed ID: 12637480 [TBL] [Abstract][Full Text] [Related]
36. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects. Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086 [TBL] [Abstract][Full Text] [Related]
37. Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. Sarcar B; Kahali S; Chinnaiyan P J Neurooncol; 2010 Sep; 99(2):201-7. PubMed ID: 20135194 [TBL] [Abstract][Full Text] [Related]
38. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in p53 mutant human colon cancer. Tanaka K; Inoue Y; Hiro J; Yoshiyama S; Toiyama Y; Eguchi T; Miki C; Kusunoki M J Exp Clin Cancer Res; 2007 Jun; 26(2):241-51. PubMed ID: 17725105 [TBL] [Abstract][Full Text] [Related]
39. In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs. Bernacki RJ; Pera P; Gambacorta P; Brun Y; Greco WR Ann N Y Acad Sci; 2000; 922():293-7. PubMed ID: 11193904 [TBL] [Abstract][Full Text] [Related]
40. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]